Role of MicroRNA-124 as a Prognostic Factor in Multiple Neoplasms: A Meta-Analysis

Table 4

Pooled information for overall survival or disease-free survival/recurrence-free survival stratified by ethnicity and main pathological type for overall and subgroup analyses.

Subgroup	OS					DFS/PFS
		HR/95% CI	value		PN		HR/95% CI	value		PN
Total	23	0.55 (0.50-0.61)	<0.001	58.9%	2253	12	0.48 (0.38-0.61)	0.013	54.0%	1228
Cancer type
Lung cancer	5	0.43 (0.25-0.73)	0.006	72.6%	641	2	0.25 (0.12, 0.53)	0.482	0.0%	256
HCC	3	0.56 (0.40-0.78)	0.049	66.6%	307	2	0.43 (0.26, 0.70)	0.782	0.0%	286
Colorectal	2	0.20 (0.08-0.50)	0.763	0.0%	145	2	0.39 (0.14, 1.07)	0.095	64.0%	145
Breast cancer	2	0.39 (0.21-0.71)	0.453	0.0%	181	NM
Osteosarcoma	2	0.42 (0.18-1.00)	0.119	58.8%	219	1	0.25 (0.13, 0.52)	<0.001	0.0%	114
PDAC	2	0.55 (0.35-0.86)	0.171	46.6%	118	NM
Cervical cancer	2	0.41 (0.18-0.97)	0.604	0.0%	167	1	0.63 (0.15, 2.63)	<0.001	0.0%	40
Gastric cancer	2	0.46 (0.31-0.68)	0.549	0.0%	209	1	0.62 (0.33, 1.17)	<0.001	0.0%	121
ccRCC	1	0.38 (0.15-0.99)	<0.001	0.0%	62	1	0.49 (0.18, 1.30)	<0.001	0.0%	62
Ependymoma	1	5.40 (1.81-16.10)	<0.001	0.0%	67	1	2.40 (1.01-5.73)	<0.001	0.0%	67
Glioma	1	0.55 (0.30-1.00)	<0.001	0.0%	137	1	0.56 (0.32, 0.97)	<0.001	0.0%	137
Ethnicity
Asian	21	0.48 (0.41-0.57)	0.015	44.7%	2124	10	0.42 (0.33, 0.55)	0.360	9.0%	1099
Caucasian	2	1.42 (0.11-18.90)	<0.001	92.2%	129	2	1.10 (0.23, 5.26)	0.017	82.5%	129
Source of HR
Reported	16	0.48 (0.37-0.61)	<0.001	71.9%	1600	7	0.45 (0.24, 0.83)	0.001	72.4%	683
Survival curve	7	0.51 (0.39-0.66)	0.861	0.0%	653	5	0.51 (0.37, 0.71)	0.743	0.0%	545

PN: patient numbers; Colorectal: colorectal cancer.